Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.

Abstract

We compared the efficacy of bimonthly intravitreal injections of ranibizumab (IVR) with that of bimonthly intravitreal injections of aflibercept (IVA) in two prospective, consecutive groups of patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO). Eyes with ME after CRVO received either bimonthly IVR (ranibizumab group; n=13) or IVA (aflibercept group; n=13) injections and were followed monthly for 6months. Three patients in the ranibizumab group and two in the aflibercept group were lost to follow-up and excluded from the study. The best-corrected visual acuity (BCVA), central foveal thickness (CFT) on optical coherence tomography, and aqueous vascular endothelial growth factor (VEGF) concentrations were evaluated before and after treatment. From baseline to month 6, significant improvements occurred in mean logMAR BCVA (ranibizumab group: 0.78-0.47; p<0.05; aflibercept group: 0.74-0.54; p<0.05) and mean CFT (ranibizumab group: 685-311µm; p<0.05; aflibercept group: 695-230µm; p<0.05). Fluctuations in CFT were seen at months 2, 4, and 6 in the ranibizumab group. Mean aqueous VEGF concentration decreased from baseline to month 2 in the ranibizumab group (509.9-348.2pg/ml) and aflibercept group (412.1pg/ml to undetectable limits in eight of 11 eyes and to 13.6, 15.6, and 24.1pg/ml in the other three eyes, respectively). There was no significant improvement of visual acuity in one group compared with another; VEGF may not be completely neutralized by bimonthly injections of ranibizumab.